Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications

Table 1 Baseline demographic and clinical characteristics of included patients

	No Pseudomonas aeruginosa colonization (n = 255)	Pseudomonas aeruginosa colonization (n = 95)	P values
Age (years), mean ± SD	67.6 ± 13	68.5 ± 11.9	0.595
Age range (years)	20–98	25–88	0.595
Male	107 (30.5%)	26 (27.4%)	0.012*
Smoking status			0.056
Ever-smoker	68 (26.7%)	16 (16.8%)
Non-smoker	187 (73.3%)	79 (83.2%)
Daily sputum volume (mL)	6.24 ± 13.5	17.4 ± 20.4	< 0.001*
FEV₁ (L)	1.84 ± 0.62	1.40 ± 0.57	< 0.001*
FVC (L)	2.75 ± 1.12	2.18 ± 0.7	< 0.001*
Extent of involvement ≥ 3 lobes	86 (33.7%)	63 (66.3%)	< 0.001*
All exacerbations	39 (15.3%)	44 (46.3%)	< 0.001*
Exacerbations requiring hospitalization	16 (6.3%)	23 (24.2%)	< 0.001*
Co-existing respiratory conditions
Tuberculosis	48 (18.8%)	24 (25.2%)	0.185
NTM colonization	28 (11.0%)	18 (18.9%)	0.050
Asthma	24 (9.4%)	11 (11.6%)	0.357
COPD	20 (7.8%)	6 (6.3%)	0.687
Treatment
Long term macrolide use	9 (3.5%)	17 (17.9%)	< 0.001*
Inhaled corticosteroid use	58 (22.7%)	50 (52.6%)	< 0.001*
Regular intravenous antibiotics administration	0 (0%)	9 (9.5%)	< 0.001*
Nebulized antibiotics	1 (0.40%)	2 (2.10%)	0.056

SD standard deviation, mL milliliter; *Statistically significant; FEV₁ forced expiratory volume in one second, FVC forced vital capacity, NTM non-tuberculous mycobacterium, COPD chronic obstructive pulmonary disease

ISSN: 1465-993X